Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.680
-0.110 (-2.30%)
At close: Oct 3, 2024, 4:00 PM
4.650
-0.030 (-0.64%)
After-hours: Oct 3, 2024, 6:39 PM EDT
Aquestive Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 58.36 | 50.58 | 47.68 | 50.83 | 45.85 | 52.61 | Upgrade
|
| Revenue Growth (YoY) | 25.45% | 6.09% | -6.20% | 10.87% | -12.85% | -21.98% | Upgrade
|
| Cost of Revenue | 18.39 | 20.83 | 19.39 | 14.99 | 12.96 | 20.36 | Upgrade
|
| Gross Profit | 39.97 | 29.75 | 28.29 | 35.84 | 32.89 | 32.25 | Upgrade
|
| Selling, General & Admin | 38.98 | 31.75 | 52.88 | 53.48 | 55.89 | 64.34 | Upgrade
|
| Research & Development | 16.18 | 13.1 | 17.48 | 17.05 | 19.89 | 20.57 | Upgrade
|
| Operating Expenses | 55.16 | 44.85 | 70.36 | 70.52 | 75.78 | 84.92 | Upgrade
|
| Operating Income | -15.19 | -15.1 | -42.07 | -34.68 | -42.89 | -52.67 | Upgrade
|
| Interest Expense | -12.94 | -7.46 | -12.44 | -22.46 | -13.02 | -9.32 | Upgrade
|
| Interest & Investment Income | 3.4 | 16.32 | 0.1 | 0.42 | 0.13 | 0.64 | Upgrade
|
| EBT Excluding Unusual Items | -24.73 | -6.24 | -54.41 | -56.72 | -55.78 | -61.35 | Upgrade
|
| Other Unusual Items | -1.03 | -1.38 | - | -13.82 | - | -4.9 | Upgrade
|
| Pretax Income | -25.76 | -7.63 | -54.41 | -70.54 | -55.78 | -66.25 | Upgrade
|
| Income Tax Expense | -0.04 | 0.25 | - | - | - | - | Upgrade
|
| Net Income | -25.72 | -7.87 | -54.41 | -70.54 | -55.78 | -66.25 | Upgrade
|
| Net Income to Common | -25.72 | -7.87 | -54.41 | -70.54 | -55.78 | -66.25 | Upgrade
|
| Shares Outstanding (Basic) | 74 | 61 | 49 | 38 | 34 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 74 | 61 | 49 | 38 | 34 | 25 | Upgrade
|
| Shares Change (YoY) | 34.20% | 25.69% | 27.99% | 13.15% | 32.71% | 22.34% | Upgrade
|
| EPS (Basic) | -0.35 | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 | Upgrade
|
| EPS (Diluted) | -0.35 | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 | Upgrade
|
| Free Cash Flow | -24.91 | -7.38 | -10.84 | -33.89 | -45.98 | -60.87 | Upgrade
|
| Free Cash Flow Per Share | -0.34 | -0.12 | -0.22 | -0.89 | -1.37 | -2.40 | Upgrade
|
| Gross Margin | 68.49% | 58.82% | 59.34% | 70.51% | 71.72% | 61.30% | Upgrade
|
| Operating Margin | -26.03% | -29.86% | -88.23% | -68.22% | -93.55% | -100.11% | Upgrade
|
| Profit Margin | -44.07% | -15.56% | -114.11% | -138.77% | -121.67% | -125.92% | Upgrade
|
| Free Cash Flow Margin | -42.68% | -14.58% | -22.74% | -66.67% | -100.28% | -115.71% | Upgrade
|
| EBITDA | -14.02 | -13.73 | -39.51 | -31.53 | -39.29 | -49.62 | Upgrade
|
| EBITDA Margin | -24.02% | -27.14% | -82.87% | -62.02% | -85.68% | -94.32% | Upgrade
|
| D&A For EBITDA | 1.17 | 1.37 | 2.55 | 3.15 | 3.61 | 3.05 | Upgrade
|
| EBIT | -15.19 | -15.1 | -42.07 | -34.68 | -42.89 | -52.67 | Upgrade
|
| EBIT Margin | -26.03% | -29.86% | -88.23% | -68.22% | -93.55% | -100.11% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.